BioSpace News Archive

Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientia’s discretion Financing led by SoftBank Vision Fund 2

Renzo DiCarlo, CEO of BioPharma Services Inc. was proud to be invited to appear as a witness before the House of Commons’ Standing Committee on International Trade, in view of its study entitled Canada’s International Trade and Investment Policy: Selected Considerations Concerning COVID-19 Vaccines . As a London School of Economics (LSE) alumnus in stakeholder theory research with 25 years of experience in Pharmace

Noven Pharmaceuticals, Inc., (“Noven”) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced it will present the results of a multicenter, phase 2, laboratory classroom study which evaluated the safety and efficacy of its investigational dextroamphetamine transdermal system (“ATS”) in over 100 pediatric patients (ages 6-17 years) with ADHD at the 2021 virtual American Psychiatric Association

BioTek reMEDys, one of the nation’s largest specialty infusion pharmacies focused on rare diseases, is celebrating its 10th anniversary this month, having first incorporated in April of 2011.

Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces its financial results for the fiscal year ended December 31, 2020.

Bench International, a leading global executive search firm, announces the addition of industry veteran, Linda Sierra, to serve as Senior Vice President, Business Development.

Paradigm4 unveiled its scalable solution for efficiently working with the Allotrope Data Format (ADF) at the Allotrope Foundation’s Spring Connect meeting (19-26th April 2021).

Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced it will release its financial results for the first quarter of 2021 on Tuesday, May 11, 2021.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that the Company will provide a corporate and financial update for the first quarter 2021, on Thursday, May 6, 2021, before the market opens.

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.